Clinical Method Claims Dodge a Bullet: Prometheus v. Mayo


On December 17, 2010, the U.S. Court of Appeals for the Federal Circuit confirmed that claims to clinical and diagnostic methods can constitute patent-eligible subject matter in its Prometheus II,1 decision. This was one of the first Federal Circuit opinions applying the recent United States Supreme Court Bilski case, which interpreted the statutory requirements for patent eligibility under 35 U.S.C. § 101.2

In Prometheus II, the Federal Circuit essentially reaffirmed its earlier decision in Prometheus I,3 holding that the claims recite a patent-eligible application of naturally occurring correlations and do not wholly preempt all uses of such correlations. Prometheus II clarifies that after Bilski, clinical and diagnostic methods can still be patented.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.